Sun Pharmaceutical Industries Limited has announced the launch of FEXUCLUE® (Fexuprazan) 40 mg tablets in India, a novel treatment for Erosive Esophagitis. FEXUCLUE® is a Potassium-Competitive Acid Blocker (PCAB) that offers a new and effective option for adult patients suffering from all grades of this condition.
Sun Pharma has partnered with Daewoong Pharmaceutical Co. Ltd., Korea, acquiring exclusive rights to manufacture and commercialize FEXUCLUE® in India. The agreement includes upfront, milestone payments, and royalty terms.
Kirti Ganorkar, CEO – India Business, Sun Pharma, commented, “Erosive Esophagitis is a serious condition that greatly affects patients’ quality of life. Despite available treatments, there remains a significant unmet need in its management. FEXUCLUE® is a best-in-class treatment option with the potential to bridge this gap. At Sun Pharma, we are committed to introducing innovative medicines that enhance patients’ quality of life.”
A Phase 3 clinical study conducted in India demonstrated the drug’s efficacy and safety. Over 95% of patients achieved healing of Erosive Esophagitis within 8 weeks, confirmed through endoscopic examination. The treatment was well tolerated among Indian patients.
With the launch of FEXUCLUE®, Sun Pharma continues its commitment to bringing innovative, patient-centric therapies to the Indian healthcare market.
